News

Sanofi to launch new products for Rare diseases in India

Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India

Sanofi Speciality Care reaffirmed its commitment to rare diseases in India on the occasion of Rare Disease Day. The company has also received a recommendation from the Subject Expert Committee to import and market two new products in India — Nexviazyme (Avalglucosidase alfa powder) and Xenpozyme (Olipudase alfa powder) for Pompe disease and Niemann-Pick disease (ASMD) respectively. “We are hoping to launch these therapies in India by end of 2023 or the beginning of next year, subject to completion of all further regulatory steps.”

Both these products have been granted orphan drug status and approval in several countries including the US, Australia, EU, UK and Japan, to name a few. 

Dr Shalini Menon, Country Medical Lead, Sanofi, “Xenpozyme is the first therapy indicated specifically for the treatment of ASMD, and is currently the only approved treatment for this disease. This is a devastating and extremely rare disease that affects both children and adults. The approval of Xenpozyme represents the culmination of bold work done in research and development, and Sanofi’s unwavering commitment to this historically overlooked community.” She said Nexviazyme is for both infantile and late-onset Pompe disease and showed improvements in respiratory function and walking distance measures.”

Anil Raina, GM, Sanofi Speciality Care (India) said, “Over the past 40 years, Sanofi has launched different therapies for the treatment of many rare diseases, namely Gaucher disease, Fabry disease, Pompe disease, Mucopolysaccharidosis I (MPS I) and Acid Sphingomyelinase deficiency (ASMD). Since its incorporation in India in 2007, we have been working not only towards enhancing awareness of rare diseases, providing free diagnostic support, but also building the capacity of the clinicians, and supporting Centres of Excellence (CoEs) in public and private institutions.”

Raina added, “The company also has a global humanitarian program aimed at providing free life-saving treatment to patients in India diagnosed with Lysosomal Storage Disorders (LSDs). Under our India Charitable Access Program (INCAP), we have been supporting patients with Gaucher disease, Pompe disease, Fabry disease and MPS I disease with life-saving Enzyme Replacement Therapy. Many of the children receiving therapy under this programme are now in their teens and adulthood, and can lead near-normal lives.”

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close